Literature DB >> 23293836

Cathepsin B as a cancer target.

Christopher S Gondi1, Jasti S Rao.   

Abstract

INTRODUCTION: Cathepsin B is of significant importance to cancer therapy as it is involved in various pathologies and oncogenic processes in humans. Numerous studies have shown that abnormal regulation of cathepsin B overexpression is correlated with invasive and metastatic phenotypes in cancers. Cathepsin B is normally associated with the lysosomes involved in autophagy and immune response, but its aberrant expression has been shown to lead to cancers. AREAS COVERED: This review highlights the oncogenic role of cathepsin B, discusses the regulation of cathepsin B in light of oncogenesis, discusses the role of cathepsin B as a signaling molecule, and highlights the therapeutic potential of targeting cathepsin B. EXPERT OPINION: Targeting cathepsin B alone does not appear to abolish tumor growth, and this is probably because cathepsin B appears to have diverse functions and influence numerous pathways. It is not clear whether global suppression of cathepsin B activity or expression would produce unintended effects or cause the activation or suppression of unwanted pathways. A localized approach for targeting the expression of cathepsin B would be more relevant. Moreover, a combination of targeting cathepsin B with other relevant oncogenic molecules has significant therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23293836      PMCID: PMC3587140          DOI: 10.1517/14728222.2013.740461

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  112 in total

1.  Physiological mechanisms for metalloproteinase activation.

Authors:  G Murphy; R Ward; J Gavrilovic; S Atkinson
Journal:  Matrix Suppl       Date:  1992

Review 2.  Cathepsin-regulated apoptosis.

Authors:  C E Chwieralski; T Welte; F Bühling
Journal:  Apoptosis       Date:  2006-02       Impact factor: 4.677

3.  Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells.

Authors:  Santhi D Konduri; Niranjan Yanamandra; Khawar Siddique; Arun Joseph; Dzung H Dinh; William C Olivero; Meena Gujrati; Gregory Kouraklis; Amand Swaroop; Athanassios P Kyritsis; Jasti S Rao
Journal:  Oncogene       Date:  2002-12-12       Impact factor: 9.867

4.  Cathepsin T (convertase) generates the multiple forms of tyrosine aminotransferase by limited proteolysis.

Authors:  J L Hargrove; E Gohda; H C Pitot; D K Granner
Journal:  Biochemistry       Date:  1982-01-19       Impact factor: 3.162

Review 5.  Molecular regulation, membrane association and secretion of tumor cathepsin B.

Authors:  B A Frosch; I Berquin; M R Emmert-Buck; K Moin; B F Sloane
Journal:  APMIS       Date:  1999-01       Impact factor: 3.205

6.  Cathepsin L. A new proteinase from rat-liver lysosomes.

Authors:  H Kirschke; J Langner; B Wiederanders; S Ansorge; P Bohley
Journal:  Eur J Biochem       Date:  1977-04-01

7.  Isolation and characterization of human cathepsin V: a major proteinase in corneal epithelium.

Authors:  W Adachi; S Kawamoto; I Ohno; K Nishida; S Kinoshita; K Matsubara; K Okubo
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-09       Impact factor: 4.799

8.  Cathepsin B is involved in the trafficking of TNF-alpha-containing vesicles to the plasma membrane in macrophages.

Authors:  Soon-Duck Ha; Andrew Martins; Khashayarsha Khazaie; Jiahuai Han; Bosco M C Chan; Sung Ouk Kim
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Evidence that E-box promoter elements and MyoD transcription factors play a role in the induction of cathepsin B gene expression during human myoblast differentiation.

Authors:  Derek T Jane; Leslie C Morvay; Jennifer Koblinski; Shiqing Yan; Fawzy A Saad; Bonnie F Sloane; Michael J Dufresne
Journal:  Biol Chem       Date:  2002-12       Impact factor: 3.915

10.  Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons.

Authors:  Qiuli Liang; Xiaosen Ouyang; Lonnie Schneider; Jianhua Zhang
Journal:  Mol Neurodegener       Date:  2011-06-01       Impact factor: 14.195

View more
  89 in total

Review 1.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

2.  Functional selection of protease inhibitory antibodies.

Authors:  Tyler Lopez; Zahid Mustafa; Chuan Chen; Ki Baek Lee; Aaron Ramirez; Chris Benitez; Xin Luo; Ru-Rong Ji; Xin Ge
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-30       Impact factor: 11.205

Review 3.  Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes.

Authors:  Reik Löser; Jens Pietzsch
Journal:  Front Chem       Date:  2015-06-23       Impact factor: 5.221

4.  Activity of plasma membrane V-ATPases is critical for the invasion of MDA-MB231 breast cancer cells.

Authors:  Kristina Cotter; Joseph Capecci; Souad Sennoune; Markus Huss; Martin Maier; Raul Martinez-Zaguilan; Michael Forgac
Journal:  J Biol Chem       Date:  2014-12-10       Impact factor: 5.157

5.  Cathepsins in heart disease-chewing on the heartache?

Authors:  Jordan Blondelle; Stephan Lange; Barry H Greenberg; Randy T Cowling
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

6.  Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.

Authors:  Lukáš Tenora; Jesse Alt; Ranjeet P Dash; Alexandra J Gadiano; Kateřina Novotná; Vijayabhaskar Veeravalli; Jenny Lam; Quinn R Kirkpatrick; Kathryn M Lemberg; Pavel Majer; Rana Rais; Barbara S Slusher
Journal:  J Med Chem       Date:  2019-03-29       Impact factor: 7.446

7.  Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor.

Authors:  Wei Fan; Wenting Zhang; Sameer Alshehri; Trey R Neeley; Jered C Garrison
Journal:  Eur J Med Chem       Date:  2019-05-25       Impact factor: 6.514

8.  Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program.

Authors:  Haitao Luan; Bhopal Mohapatra; Timothy A Bielecki; Insha Mushtaq; Sameer Mirza; Tameka A Jennings; Robert J Clubb; Wei An; Dena Ahmed; Rokaya El-Ansari; Matthew D Storck; Nitish K Mishra; Chittibabu Guda; Yuri M Sheinin; Jane L Meza; Srikumar Raja; Emad A Rakha; Vimla Band; Hamid Band
Journal:  Cancer Res       Date:  2018-03-06       Impact factor: 12.701

9.  Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and S-denitrosylase.

Authors:  Irina Pader; Rajib Sengupta; Marcus Cebula; Jianqiang Xu; Jon O Lundberg; Arne Holmgren; Katarina Johansson; Elias S J Arnér
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

10.  The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L.

Authors:  Bailey Miller; Aaron J Friedman; Hyukjae Choi; James Hogan; J Andrew McCammon; Vivian Hook; William H Gerwick
Journal:  J Nat Prod       Date:  2013-12-23       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.